Trial reportMedicine2019
Circulating alarin concentrations are high in patients with type 2 diabetes and increased by glucagon-like peptide-1 receptor agonist treatment: An Consort-compliant study.
Trial report in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06333548 (Comparison of Cord Blood Alarin Levels in Term Babies According to Birth Weight), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Cord Blood Alarin Levels in Term Babies According to Birth Weight
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Alarin as a potential biomarker in childhood obesity: Evidence from a case-control study.Medicine · 2026Article
- Serum levels of galanin-like peptide and alarin are highly correlated with polycystic ovary syndrome.Scientific reports · 2025Article
- Comparison of cord blood alarin levels of full-term infants according to birth weight.Journal of perinatal medicine · 2025Article
- Androgenetic Alopecia and Metabolic Syndrome: Is Alarin a Missing Link?The Journal of clinical and aesthetic dermatology · 2022Article
- The evolving roles of alarin in physiological and disease conditions, and its future potential clinical implications.Frontiers in endocrinology · 2022Review
- Regulatory effects and potential therapeutic implications of alarin in depression, and arguments on its receptor.Frontiers in psychiatry · 2022Review
- Alarin alleviated cardiac fibrosis via attenuating oxidative stress in heart failure rats.Amino acids · 2021Article
- Plasma Alarin Level and Its Influencing Factors in Obese Newly Diagnosed Type 2 Diabetes Patients.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextAlarin has been reported to be relative to food intake and an increase in body weight. However, to date, no report has demonstrated the relationship between circulating alarin and diabetes in humans.
objectiveThe objective of this study is to gain insight into the possible role of alarin in humans. DESIGN AND
methods164 patients with newly diagnosed type 2 diabetes mellitus (nT2DM), 112 IGT and 134 healthy subjects were recruited for this study. In an interventional study, 29 nT2DM patients were treated by a weekly GLP-1RA for 6 months. Plasma alarin concentrations were measured by ELISA.
resultsCirculating alarin concentrations were significantly higher in both IGT and nT2DM subjects than in healthy individuals (0.40 ± 0.14 and 0.54 ± 0.24 vs 0.37 ± 0.10 μg/L, P < .05 or P < .01), whereas in T2DM patients, circulating alarin levels were higher than in IGT subjects. Circulating alarin positively correlated with FBG, HbA1c, HOMA-IR, AUCglucose and TNFα (P < .05 or P < .01). Multivariate logistic regression revealed that circulating alarin levels were correlated with IGT and T2DM. GLP-1RA treatment for 6 months increased circulating alarin levels in T2DM patients (from 0.34 ± 0.10 for baseline, to 0.39 ± 0.14 for 12 weeks, and finally to 0.38 ± 0.15 μg/L for 24 weeks; vs. pre-treatment P < .05).
conclusionsThese data suggest that alarin might be involved in the pathogenesis of T2DM in humans. CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-OCS-13003185 (18/03/2013 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.